ClinicalTrials.gg
RecruitingNCT07235462ACO-REALUpdated Oct 8, 2026

A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting

An observational study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM), sponsored by Bayer. Recruiting at 17 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Bayer · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Oct 8, 2026First sites in 16 new countriesStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up as amyloid fibrils in the heart muscle. This buildup causes the heart to become stiff, leading to restrictive cardiomyopathy and progressive heart failure. There are two forms of ATTR-CM: a hereditary or 'variant' form (vATTR-CM) caused by a gene mutation, and a 'wild-type' form (wtATTR-CM) which is associated with aging. Because its symptoms can be similar to other heart conditions, ATTR-CM is often diagnosed late. However, recent advances in medical imaging are helping doctors to identify the disease earlier. Acoramidis is a new medication designed to treat ATTR-CM. It works by stabilizing the TTR protein, preventing it from misfolding and forming the harmful amyloid deposits. Acoramidis has been shown to be effective and safe in a major clinical trial (the ATTRibute-CM study), which led to its approval for use in both the United States and Europe. While clinical trials provide valuable information, data on how a new medicine performs in everyday clinical practice is also very important. This type of information is called real-world evidence. Currently, there is limited real-world information about the use of acoramidis. This study, called ACO-REAL, is an observational study, which means researchers will observe patients who are receiving acoramidis as part of their normal clinical care, without introducing any experimental interventions. The study will take place in approximately 20 European countries and aims to enroll up to 2,000 adults who have been diagnosed with either wild-type or variant ATTR-CM and are starting treatment with acoramidis. This includes patients who have not been treated for ATTR-CM before, as well as those who have been treated with other therapies. The main goals of the study are to understand the characteristics of patients being treated with acoramidis and to document how the treatment is used in routine medical practice. The study will also collect information on the safety of acoramidis. Furthermore, researchers will assess how the treatment affects patients' heart function, their functional capacity (such as their ability to walk), their overall health status, and their quality of life. The study will also track how often patients need to use healthcare resources like hospitals or emergency rooms. This information will help to improve the understanding and management of ATTR-CM in a real-world setting, ultimately aiming to optimize care for patients with this progressive disease.

02

Conditions studied

  • Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Keywords

  • Transthyretin Amyloidosis
  • Cardiomyopathy
  • Heart Failure
  • Wild-type Amyloidosis
03

In context

Amyloidosis, Hereditary, Transthyretin-Related

82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 100 across 40 observational studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.

Browse Amyloidosis, Hereditary, Transthyretin-Related studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with an established diagnosis of either wild-type or variant Transthyretin Amyloid Cardiomyopathy (ATTR-CM) who are eligible for treatment with acoramidis based on the clinical decision of the investigator, made independently of the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Adults (≥18 years at the date of signing the form (ICF)).
  • Diagnosis of either wild-type or variant ATTR-CM.
  • Signed ICF.
  • Decision to initiate treatment with acoramidis was made as per treating investigator's routine treatment practice before signature of ICF.
  • Treatment start with acoramidis within 90 days after signing the ICF, with the possibility of starting acoramidis on the same day as signing the ICF.

Exclusion criteria

Exclusion Criteria:

  • Participation in an trial with interventions outside of routine clinical practice, except for participation in potential sub-studies related to this observational study. Please note: In addition to this observational study, separate sub-studies may be conducted to collect additional data. Participation in these sub-studies is voluntary and will be governed by separate protocols and processes. The main observational study does not include interventional procedures beyond routine clinical practice.

    • according to the local SmPC of acoramidis.
    • Patients who are unable to provide consent, including those whose consent would need to be given by a legal representative.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Acoramidis Arm

    Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) initiating treatment with acoramidis in routine clinical practice.

    Drug: Acoramidis (356 mg film-coated tablets)

Interventions

06

What researchers measure

Primary outcomes

  1. Patient demographic characteristics: age

    Demographic characteristics at the first documented regular visit in the study, referred to as the initial study visit.

    Time frame: Baseline (Initial study visit)

  2. Patient demographic characteristics: sex

    Demographic characteristics at the first documented regular visit in the study, referred to as the initial study visit.

    Time frame: Baseline (Initial study visit)

  3. Patient demographic characteristics: race

    Demographic characteristics at the first documented regular visit in the study, referred to as the initial study visit.

    Time frame: Baseline (Initial study visit)

  4. Patient demographic characteristics: height

    Demographic characteristics at the first documented regular visit in the study, referred to as the initial study visit.

    Time frame: Baseline (Initial study visit)

  5. Patient demographic characteristics: weight

    Demographic characteristics at the first documented regular visit in the study, referred to as the initial study visit.

    Time frame: Baseline (Initial study visit)

  6. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Type

    ATTR-CM type: mixed phenotype (yes/no)

    Time frame: Baseline up to 15 months

  7. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Genetic status

    ATTR-CM type: genetic status (mutation / wild type; if mutation: genotype and zygosity)

    Time frame: Baseline up to 15 months

  8. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis

    ATTR-CM diagnosis (year of diagnosis)

    Time frame: Baseline up to 15 months

  9. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Setting of Diagnosis

    ATTR-CM setting of diagnosis: (endomyocardial biopsy / non-invasive / both, NYHA classification at diagnosis)

    Time frame: Baseline up to 15 months

  10. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Manifestations

    ATTR-CM manifestations (type)

    Time frame: Baseline up to 15 months

  11. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) -relevant comorbidities

    ATTR-CM-relevant comorbidities (type)

    Time frame: Baseline up to 15 months

  12. Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) -relevant procedures

    Prior and concomitant ATTR-CM-relevant procedures (type)

    Time frame: Baseline up to 15 months

  13. Treatment Patterns with Acoramidis: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) -related medications

    Previously administered ATTR-CM-related medications within the past 12 months before initial visit (name)

    Time frame: Baseline (assessment within the past 12 months prior to initiation)

  14. Treatment Patterns with Acoramidis: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) concomitant medications

    Concomitant medications administered alongside acoramidis (name)

    Time frame: Baseline up to 15 months

  15. Treatment Patterns with Acoramidis: Initiation

    Acoramidis initiation (date)

    Time frame: Baseline up to 15 months

  16. Treatment Patterns with Acoramidis: Initiation after a different therapy

    Acoramidis initiation (if patient is switching from a different therapy: reason for switch)

    Time frame: Baseline up to 15 months

  17. Treatment Patterns with Acoramidis: discontinuation

    Acoramidis discontinuation (reason)

    Time frame: Baseline up to 15 months

  18. Treatment Patterns with Acoramidis: interruption

    Acoramidis interruption (reason)

    Time frame: Baseline up to 15 months

  19. Treatment Patterns with Acoramidis: prescription / refills

    Acoramidis prescriptions/refills since the last visit or telephone contact (duration of time from initiation to discontinuation of therapy)

    Time frame: Baseline up to 15 months

Secondary outcomes

  1. Incidence of Adverse Events

    Adverse events (AEs) documentation

    Time frame: From acoramidis initiation up to end of observation (approximately 12-15 months).

  2. Incidence of Serious Adverse Events

    Serious Adverse events (SAEs) documentation

    Time frame: From acoramidis initiation up to end of observation (approximately 12-15 months).

07

Study locations

17 of 17 sites recruiting
  • Many Locations
    Multiple Locations, Austria
    Recruiting
  • Many Locations
    Multiple Locations, Belgium
    Recruiting
  • Many Locations
    Multiple Locations, Croatia
    Recruiting
  • Many Locations
    Multiple Locations, Denmark
    Recruiting
  • Many Locations
    Multiple Locations, Estonia
    Recruiting
  • Many Locations
    Multiple Locations, Finland
    Recruiting
  • Many Locations
    Multiple Locations, Germany
    Recruiting
  • Many Locations
    Multiple Locations, Italy
    Recruiting
  • Many Locations
    Multiple Locations, Latvia
    Recruiting
  • Many Locations
    Multiple Locations, Lithuania
    Recruiting
  • Many Locations
    Multiple Locations, Norway
    Recruiting
  • Many Locations
    Multiple Locations, Portugal
    Recruiting
  • Many Locations
    Multiple Locations, Slovenia
    Recruiting
  • Many Locations
    Multiple Locations, Spain
    Recruiting
  • Many Locations
    Multiple Locations, Sweden
    Recruiting
  • Many Locations
    Multiple Locations, Switzerland
    Recruiting
  • Many Locations
    Multiple Locations, United Kingdom
    Recruiting
08

References and documents

Publications

  • Fontana M, Cappelli F, Gillmore JD, Obici L, Siepen FAD, Debonnaire P, Gonzalez-Lopez E, Schulze M, Vogtlander K, Ciaccia A, Merz M, Garcia-Pavia P. Rationale and Design of ACO-REAL: A Real-World Non-Interventional Study of Acoramidis in Routine Clinical Practice. Cardiol Ther. 2026 Jul 31. doi: 10.1007/s40119-026-00461-9. Online ahead of print. PubMed 42533192 ↗

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2028, 30 months after the start.

Of 25 observational studies under Amyloidosis, Hereditary, Transthyretin-Related, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 97. This study's planned 30 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2028 → Apr 2028, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2025
First posted
Nov 19, 2025
StartActual
Oct 29, 2025
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028was Jul 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
17 sites added, 1 site removed — first sites in Austria, Belgium, Croatia, Denmark, Estonia and 11 more
All 16 countries

Austria, Belgium, Croatia, Denmark, Estonia, Finland, Italy, Latvia, Lithuania, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland, United Kingdom

Show 17 added (1 Austria, 1 Belgium, 1 Croatia, 1 Denmark, 1 Estonia, 1 Finland, 1 Germany, 1 Italy, 1 Latvia, 1 Lithuania, 1 Norway, 1 Portugal, 1 Slovenia, 1 Spain, 1 Sweden, 1 Switzerland, 1 United Kingdom)
  • Many Locations · Multiple Locations, Austria
  • Many Locations · Multiple Locations, Belgium
  • Many Locations · Multiple Locations, Croatia
  • Many Locations · Multiple Locations, Denmark
  • Many Locations · Multiple Locations, Estonia
  • Many Locations · Multiple Locations, Finland
  • Many Locations · Multiple Locations, Germany
  • Many Locations · Multiple Locations, Italy
  • Many Locations · Multiple Locations, Latvia
  • Many Locations · Multiple Locations, Lithuania
  • Many Locations · Multiple Locations, Norway
  • Many Locations · Multiple Locations, Portugal
  • Many Locations · Multiple Locations, Slovenia
  • Many Locations · Multiple Locations, Spain
  • Many Locations · Multiple Locations, Sweden
  • Many Locations · Multiple Locations, Switzerland
  • Many Locations · Multiple Locations, United Kingdom
Show 1 removed
  • Universitaetsklinik Heidelberg · Heidelberg, Germany
Oct 8, 2026
Study completion
Jul 3, 2028→Apr 30, 2028
Oct 8, 2026
Contact
Study contact's phone or email changed: •••2937→•••8422. See the current contact
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    17 sites added, 1 site removed — first sites in Austria, Belgium, Croatia, Denmark, Estonia and 11 more
    All 16 countries

    Austria, Belgium, Croatia, Denmark, Estonia, Finland, Italy, Latvia, Lithuania, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland, United Kingdom

    Show 17 added (1 Austria, 1 Belgium, 1 Croatia, 1 Denmark, 1 Estonia, 1 Finland, 1 Germany, 1 Italy, 1 Latvia, 1 Lithuania, 1 Norway, 1 Portugal, 1 Slovenia, 1 Spain, 1 Sweden, 1 Switzerland, 1 United Kingdom)
    • Many Locations · Multiple Locations, Austria
    • Many Locations · Multiple Locations, Belgium
    • Many Locations · Multiple Locations, Croatia
    • Many Locations · Multiple Locations, Denmark
    • Many Locations · Multiple Locations, Estonia
    • Many Locations · Multiple Locations, Finland
    • Many Locations · Multiple Locations, Germany
    • Many Locations · Multiple Locations, Italy
    • Many Locations · Multiple Locations, Latvia
    • Many Locations · Multiple Locations, Lithuania
    • Many Locations · Multiple Locations, Norway
    • Many Locations · Multiple Locations, Portugal
    • Many Locations · Multiple Locations, Slovenia
    • Many Locations · Multiple Locations, Spain
    • Many Locations · Multiple Locations, Sweden
    • Many Locations · Multiple Locations, Switzerland
    • Many Locations · Multiple Locations, United Kingdom
    Show 1 removed
    • Universitaetsklinik Heidelberg · Heidelberg, Germany
    Study completion Jul 3, 2028→Apr 30, 2028
    Contact Study contact's phone or email changed: •••2937→•••8422. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07235462
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Oct 29, 2025
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
0018888422 ext. 937

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion